Valuation: PolyPid Ltd.

Market Cap 98.75M 86.55M 80M 73.58M 139M 9.52B 141M 957M 375M 4.66B 371M 363M 16.05B P/E 2026 *
-3.61x
P/E 2027 * -4.1x
Enterprise Value 98.75M 86.55M 80M 73.58M 139M 9.52B 141M 957M 375M 4.66B 371M 363M 16.05B EV / Sales 2026 *
-
EV / Sales 2027 * 7.22x
Free-Float
78.77%
Yield 2026 *
-
Yield 2027 * -
1 day-4.10%
1 week+2.18%
Current month+1.38%
1 month+8.65%
3 months+9.81%
6 months+15.47%
Current year+18.66%
1 week 5.06
Extreme 5.06
5.73
1 month 4.53
Extreme 4.53
5.73
Current year 4.01
Extreme 4.01
5.73
1 year 3.06
Extreme 3.06
5.73
3 years 2.3
Extreme 2.3
12
5 years 2.3
Extreme 2.3
289.2
10 years 2.3
Extreme 2.3
583.5
Manager TitleAgeSince
Chief Executive Officer 52 01/07/2022
Director of Finance/CFO 39 -
Chief Tech/Sci/R&D Officer 61 18/08/2025
Director TitleAgeSince
Director/Board Member 84 01/04/2008
Director/Board Member 52 08/08/2022
Director/Board Member 74 01/12/2018
Date Insider Type Main position Quantity % Market Cap.
7/15/26 A Free

Director

9,132 0.0896%
7/15/26 A Free

Director

9,132 0.0896%
7/15/26 A Free

Director

9,132 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
-4.10%+2.18%+42.27%-50.97% 103M
-2.73%-2.96%+48.62%+147.27% 1,051B
-1.67%-3.47%+52.00%+47.77% 609B
-0.44%+2.17%+33.88%+78.20% 450B
-0.75%-1.46%+28.32%+22.33% 330B
-1.52%-0.95%+33.38%+38.39% 284B
-1.70%-3.54%+20.26%+17.88% 263B
-0.58%+1.78%-20.89%-38.37% 223B
-0.58%+1.03%+23.55%+56.14% 198B
-0.80%+1.38%+23.09%+66.64% 167B
Average -1.09%+0.75%+28.45%+38.53% 357.52B
Weighted average by Cap. -0.89%+0.02%+35.25%+71.52%

Financials

2026 *2027 *
Net sales - 13.68M 11.99M 11.08M 10.19M 19.23M 1.32B 19.53M 132M 51.93M 645M 51.35M 50.23M 2.22B
Net income -33.91M -29.72M -27.48M -25.27M -47.68M -3.27B -48.44M -329M -129M -1.6B -127M -125M -5.51B -32.76M -28.71M -26.54M -24.41M -46.06M -3.16B -46.8M -317M -124M -1.55B -123M -120M -5.33B
Net Debt - -
Logo PolyPid Ltd.
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Employees
72
Date Price Change Volume
20/07/26 $5.150 -4.10% 162,338
17/07/26 $5.370 +3.47% 241,797
16/07/26 $5.190 -0.38% 188,931
15/07/26 $5.210 -2.62% 141,594
14/07/26 $5.350 +6.15% 222,673
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.150USD
Average target price
12.25USD
Spread / Average Target
+137.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PYPD Stock